Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Angiogenesis, the process of new blood vessel formation, plays a critical role in the growth, progression, and metastasis of breast cancer. Targeting tumor angiogenesis has been explored as a therapeutic approach. At Alfa Cytology, we specialize in the preclinical discovery of angiogenesis inhibitors and promotes the development of new therapies for breast cancer.
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) coordinate the proliferation, migration and survival of endothelial cells to promote the formation of new blood vessels to supply blood to rapidly growing tumors. Therefore, many monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting VEGF/VEGFR have been developed and approved for the treatment of breast cancer. However, these anti-VEGF therapies have limited clinical efficacy in breast cancer. Therefore, other novel anti-angiogenesis inhibitors should be explored for the treatment of breast cancer.
Fig.1 Angiogenesis and tumor vasculature. (Ayoub N. M., et al. 2022)
Metastatic breast cancer is the leading cause of morbidity and mortality in diagnosed patients. Cancer metastasis involves a sequential, multistep and multifunctional series of biological events that culminate in the spread of cancer cells from the primary tumor site to distant sites. In this complex process, angiogenesis is a crucial early step in the metastatic cascade. Researchers develop novel angiogenesis inhibitors for the treatment of metastatic breast cancer.
| Target | Therapeutics | Register ID | Phase |
| Fibroblast Growth Factor Receptor (FGFR) inhibitors | Erdafitinib,fulvestrant,and palbociclib | NCT03238196 | |
| Futibatinib | NCT02052778 | ||
| RLY-4008 | NCT04526106 | ||
| Angiopoietin inhibitors | Trebananib and standard therapies | NCT01042379 | |
| Interleukin agonists | Efineptakin alfa and pembrolizumab | NCT04332653 | |
| Pegilodecakin and anticancer drugs | NCT02009449 | ||
| TGF-β/TGF-βR inhibitors | Bintrafusp alfa | NCT04489940 | |
| SHR1701 and cyclin-dependent kinase 4/6 inhibitor | NCT04355858 | ||
| NIS793 and anti-PD-1 antibody | NCT02947165 | ||
| PF-06952229,palbociclib,and letrozole,or enzalutamide | NCT03685591 |
As a leading preclinical CRO, Alfa Cytology is committed to advancing the development of innovative cancer therapies, including angiogenesis inhibitors for breast cancer. Our state-of-the-art facilities and multidisciplinary team of experts provide comprehensive services to support the entire drug development process, from target identification and validation to preclinical studies and biomarker development.
Our therapeutics development platform for angiogenesis inhibitors is dedicated to targeting the crucial processes that fuel tumor growth and metastasis in breast cancer.
We work with our customers to develop new angiogenesis inhibitors for the treatment of metastatic breast cancer.
FGFR Inhibitor Development
Angiopoietin Inhibitor Development
Interleukin Agonist Development
Platelet Derived Growth Factor Inhibitor Development
Alfa Cytology provides development services for angiogenesis inhibitors, covering drug design, screening, and efficacy research to find ideal drug candidates for you and accelerate preclinical research on your breast cancer therapeutics. To learn more about our capabilities in angiogenesis inhibitor development for breast cancer or to discuss potential collaborative opportunities, please don't hesitate to contact us.
Reference
